Clinical Trial Update: Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

View source ↗

Summary

This clinical trial update reports replication data on 30-day readmission rates among nonvalvular atrial fibrillation patients treated with dabigatran, rivaroxa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Eliquis (apixaban)
• Pradaxa (dabigatran etexilate)
• Warfarin (warfarin)
• Xarelto (rivaroxaban)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Atrial Fibrillation | Status: COMPLETED